Obio Technology Shanghai Corp

Obio Technology Shanghai Corp FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Obio Technology Shanghai Corp (688238.SS) as of Oct 30, 2026 is 97.35 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 71.01 % — a change of 37.09% (higher).

FCF Conversion

97.35 %

YoY

37.09%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Obio Technology Shanghai Corp is 2025 97.35 % . FCF Conversion Rate (FCF/EBITDA) of Obio Technology Shanghai Corp was 2024 71.01 % . It decreases by 37.09% higher compared to the previous year.

The Obio Technology Shanghai Corp FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
179.40 CNY
Jan 1, 2019
161.53 CNY
Jan 1, 2020
-35.59 CNY
Jan 1, 2021
-281.63 CNY
Jan 1, 2022
-1,179.40 CNY
Jan 1, 2023
498.09 CNY
Jan 1, 2024
71.01 CNY
Jan 1, 2025
97.35 CNY
The Obio Technology Shanghai Corp FCF Conversion history
YEARFCF ConversionYoY
97.35 %+37.09%
71.01 %-85.74%
498.09 %-142.23%
-1,179.40 %+318.78%
-281.63 %+691.42%
-35.59 %-122.03%
161.53 %-9.96%
179.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Obio Technology Shanghai Corp Stock analysis

What does Obio Technology Shanghai Corp do? Obio Technology Shanghai Corp Ltd provides biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO services. The company offers contract research organization (CRO) services including gene therapy vector development and gene function research for gene therapy basic research, as well as contract research and development production organization (CDMO) services for gene drug R&D, such as pharmaceutical research and clinical sample production. It serves European and American markets and the domestic market with its CRO and CDMO offerings. The firm generates revenue through CRO services like gene therapy vector development and gene function research, and CDMO services including pharmaceutical research and clinical sample production. Its primary clients are companies involved in gene therapy and gene drug development, focusing on the European and American markets and domestic segments. The company's services support the research and development phases of gene therapy and gene drug products. Obio Technology Shanghai Corp Ltd's business model centers on providing specialized research and production services for gene therapy and gene drug development. By offering both CRO and CDMO services, it addresses key needs in the gene therapy industry, particularly in vector development and clinical sample production, targeting pharmaceutical companies and research institutions in Europe, America, and China. Obio Technology Shanghai Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Obio Technology Shanghai Corp stock

FCF Conversion Rate (FCF/EBITDA) of Obio Technology Shanghai Corp is 97.35 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Obio Technology Shanghai Corp changed from 71.01 % to 97.35 %, representing a 37.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Obio Technology Shanghai Corp since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Obio Technology Shanghai Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Obio Technology Shanghai Corp

All Key Metrics — Obio Technology Shanghai Corp